– USA, PA – iECURE, inc. a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, today announced the appointment of Brian Di Donato to its Board of Directors.
Mr. Di Donato has more than 20 years of financial and leadership experience and currently serves as CFO and head of strategy at Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies.
“Brian brings significant financial and capital market expertise to our Board, which will be helpful as we build iECURE and continue development of our pipeline of gene insertion therapies,” said CEO, Joseph Truitt. “We look forward to his guidance and support.”
About Brian Di Donato
Prior to joining Immunocore, Mr. Di Donato served as SVP and CFO at Achillion Pharmaceuticals and held leadership roles in several financial services companies, including Morgan Stanley and UBS Securities.
“iECURE has an exceptional opportunity to realize Jim Wilson’s vision of curing some of the most devastating metabolic disorders by inserting copies of healthy genes into patients’ genomes,” commented Mr. Di Donato, “I’m looking forward to helping steer the company as it embarks on this lofty mission.”
Mr. Di Donato holds an MBA from New York University’s Stern School of Business and B.S. degrees in biology from Penn State University and mechanical engineering from Villanova University. Mr. Di Donato also served in the U.S. Navy as an aerospace engineering officer.
About iECURE
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs. We are advancing our pipeline in close partnership with the world-class translational engine at the University of Pennsylvania’s Gene Therapy Program. Using in vivo editing, our methods focus on inserting functioning genes into patients’ genomes, which offers a long-term, stable expression of those genes. With our team’s proven track record, as well as the University of Pennsylvania’s deep expertise and translational genetic medicine engine, reversing the course of these devastating diseases is now within reach.
For more information: https://iecure.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.